As a biopharma founded in 2022 by Boehringer Ingelheim, Evotec and bioMérieux, AUROBAC THERAPEUTICS ambitions to become a global leader in the fight against bacterial infections, Antimicrobial Resistance (AMR) and their consequences in acute hospital settings.
We focus all our effort on identifying and developing innovative products with the ability to address clear unmet medical needs associated to bacterial infections and increasing AMR, aligned with viable clinical development plans based on a precision medicine concept. Ultimately, we want to be able to demonstrate the clinical and medico-economic value of all the products we develop and to define a new adapted and sustainable economic model in the bacterial infection and AMR field.
“The rise of Antimicrobial Resistance worldwide jeopardizes the prevention and treatment of life-threatening resistant bacterial infections, which are already killing 1.3 million people per year.
AUROBAC has the remarkable ambition to become a leader in AMR innovation with a unique combination of the best capabilities of the three founding companies, Boehringer Ingelheim, Evotec and bioMérieux.
Our strategy is to develop and commercialize safe and effective drugs using selected diagnostic approaches, to cure efficiently infected patients with minimized risks of recurrence and limited impact on disseminating resistance.”
Florence Séjourné, CEO